Grünelabs
- Company typePrivate
- Founded2019
- HeadquartersPando, Canelones, Uruguay
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
Grünelabs firmographics
Firmographics- Name
- Grünelabs
- Legal name
- Grüne Labs
- Website
- https://grunelabs.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Where Grünelabs is headquartered
LocationHeadquarters
- HQ city
- Pando, Canelones
- HQ country
- Uruguay
- HQ region
- Latin America
Offices2 records
Markets served
Grünelabs business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- B2B Extract Sales: Sale of high-quality full-spectrum cannabis extracts to business partners in the pharmaceutical industry.
- B2C Finished Product Sales: Sale of finished cannabis-based formulations (Meroflex product line) directly to patients via pharmacies and individual imports.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Grünelabs product offering
Product offeringCore offering
Grünelabs is a phytopharmaceutical company that produces full-spectrum medical cannabis extracts and finished formulations under a clone-to-bottle model. It cultivates Cannabis sativa L. using proprietary genetics, then performs extraction, formulation, and bottling in-house at GMP-certified facilities. The company sells bulk extracts to pharmaceutical partners (B2B) and finished oral drop formulations (Meroflex line) directly to patients via pharmacies and individual import mechanisms (B2C).
Product overview
Grünelabs is a phytopharmaceutical company offering a portfolio of two proprietary full-spectrum cannabis extract products—Meroflex 1:1 and Meroflex 2:1—both delivered as oral drop solutions. The company operates a clone-to-bottle model, providing cultivation, extraction, and formulation services (B2B extracts and B2C finished products). Products are currently available in Uruguay and Brazil, with expansion to European markets planned through its Portugal facility.
Differentiator
Problem solved
Functional benefit
Brands
- Meroflex 1:1: Cannabis sativa L. extract oral drops solution — CBD 1:1 THC Full Spectrum, with 2.7 g CBD and 2.5 g THC per 100 mL, in a 30 mL blue glass dropper bottle.
- Meroflex 2:1
Products and services
- Meroflex 1:1 Full-spectrum Cannabis sativa L. extract oral drops solution containing 2.7 g CBD and 2.5 g THC per 100 mL in a 1:1 ratio, presented in a 30 mL blue glass dropper bottle. Indicated for adults under medical supervision for improvement of spasticity symptoms, especially in Multiple Sclerosis. Available in Uruguay and Brazil.
- Meroflex 2:1 Full-spectrum Cannabis sativa L. extract oral drops solution containing 2.2 g CBD and 0.9 g THC per 100 mL in a 2:1 ratio, presented in a 30 mL blue glass dropper bottle. Available in Uruguay and Brazil under medical prescription.
- B2B Full-Spectrum Cannabis Extracts Sale of high-quality full-spectrum cannabis extracts in bulk to pharmaceutical industry partners requiring specific biogenetic and chemical characteristics. Produced under GMP standards from proprietary Cannabis sativa L. genetics.
- Medical Cannabis Buds (Bulk / Dried Flower) Cannabis buds and dried flower products offered as part of the company's phytopharmaceutical product portfolio, with planned production steps from cloning to drying and trimming at the Portuguese facility.
Quantifiable outcome
- Full-spectrum extract available in Uruguay and Brazil, with plans to expand to local Brazilian pharmacies and European markets
- +1 more outcomes
Companies that use Grünelabs
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Grünelabs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Grünelabs partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- University of the Republic (Universidad de la República)coreThe company's R&D department collaborates with the University of the Republic in Uruguay, receiving support for research and innovation in cannabis cultivation and extraction. This partnership provides access to a global network of university scientists and fosters knowledge exchange.
- National Research and Innovation Agency of Uruguay (ANII)minorANII provides research and innovation support to GrüneLabs' R&D department, contributing to the advancement of cannabis cultivation and extraction science in Uruguay.
- Local Universities (Portugal)coreCollaboration planned with local Portuguese universities to establish a research center focused on advancing innovation in cannabis cultivation, extraction, and final preparation. This partnership is a key component of the company's strategy to position itself as a global leader in medicinal cannabis services.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
Grünelabs competitors and assessment
Company assessmentDirect peers
- Khiron Life Sciences: Khiron is a Latin American (Colombian/now Canadian-listed) medical cannabis company with cultivation, extraction, and finished product distribution across multiple LatAm countries including Brazil. Comparable in vertical integration and Brazil/LatAm strategy.
- MediPharm Labs: MediPharm Labs is a Canadian GMP-certified cannabis extraction specialist focused on producing cannabis concentrates and APIs for pharmaceutical partners. Closely comparable as a pure-play extraction/pharma-supply peer in the medical cannabis value chain.
- Clever Leaves: Clever Leaves is a Colombian-based GMP-certified medical cannabis producer serving European and Latin American markets with cultivated flower and extracts. Direct comparator to GrüneLabs in being a LatAm-headquartered cannabis cultivator/extractor targeting pharma export markets.
- ICC Labs (now part of Aurora/ICANN): ICC Labs was a Latin American (originally Uruguayan-domiciled) medical cannabis producer with GMP operations focused on regional supply. Comparable as a historically Uruguay-anchored cannabis producer serving regional medical markets.
Broad incumbents
- Jazz Pharmaceuticals (GW Pharmaceuticals legacy): Jazz Pharmaceuticals markets Sativex (nabiximols) for Multiple Sclerosis spasticity, the same primary indication as GrüneLabs' Meroflex products. A direct botanical cannabinoid therapeutic competitor with global commercialization muscle.
- Charlotte's Web: Charlotte's Web is a US-focused full-spectrum hemp/CBD wellness company producing botanical extract products with strong consumer and pharmacy distribution. Comparable in full-spectrum botanical extract manufacturing and brand-led medical/therapeutic positioning.
- Organigram / OrganiGram Global: OrganiGram is a Canadian licensed producer with GMP-certified cultivation and processing capabilities supplying medical cannabis markets, including expansion into European and international medical channels. Comparable as a multi-country licensed medical cannabis producer.
- Tilray Brands: Tilray is a global cannabis and pharmaceutical-grade cannabis producer with GMP-certified operations across multiple countries including Portugal and Argentina, supplying medical markets in Europe and Latin America. Larger broad incumbent operating in the same medical cannabis category.
- Canopy Growth (now Canopy USA / acquired by Tilray pending): Canopy Growth operates one of the largest medical cannabis footprints including Spectrum Therapeutics medical brands and EU-GMP certified facilities across Europe and Latin America. Major broad incumbent overlapping with GrüneLabs' medical cannabis positioning.
- Aurora Cannabis: Aurora Cannabis is a major global medical cannabis producer with EU-GMP certified cultivation and processing operations across Europe and the Americas, supplying dried flower and extracts to medical markets. Comparable as a large GMP-certified medical cannabis producer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Grünelabs social profiles
Digital presenceGrünelabs compliance and trust
Trust signalCompliance3 records
Grünelabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Grünelabs leadership team
Management profileNumber of profiles
Grünelabs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Grünelabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Grünelabs
What does Grünelabs do?
Grünelabs is a phytopharmaceutical company that produces full-spectrum medical cannabis extracts and finished formulations under a clone-to-bottle model. It cultivates Cannabis sativa L. using proprietary genetics, then performs extraction, formulation, and bottling in-house at GMP-certified facilities. The company sells bulk extracts to pharmaceutical partners (B2B) and finished oral drop formulations (Meroflex line) directly to patients via pharmacies and individual import mechanisms (B2C).
Is Grünelabs a public or private company?
Grünelabs is a private company. It is classified as unknown and is currently operating.
When was Grünelabs founded?
Grünelabs was founded in 2019. It employs 1 to 10 people.
Where is Grünelabs based?
Grünelabs is headquartered in Pando, Canelones, Uruguay, in the Latin America region.
How does Grünelabs make money?
Two revenue lines are on record. B2B Extract Sales are the primary driver. The others are B2C Finished Product Sales.
Who are Grünelabs's main competitors?
Direct peers on record are Khiron Life Sciences, MediPharm Labs, Clever Leaves and ICC Labs (now part of Aurora/ICANN). Broad incumbents are Jazz Pharmaceuticals (GW Pharmaceuticals legacy), Charlotte's Web, Organigram / OrganiGram Global, Tilray Brands, Canopy Growth (now Canopy USA / acquired by Tilray pending) and Aurora Cannabis.
Does Grünelabs have an API?
No public API is recorded for Grünelabs.